Alkermes plc logo

ALKS

Alkermes plc

$27.29

Earnings Summary

Revenue
$255.24Mn
Net Profits
$-52.88Mn
Net Profit Margins
-20.72%

Highlights

Revenue:

Alkermes plc’s revenue jumped 2.62% since last year same period to $255.24Mn in the Q3 2019. On a quarterly growth basis, Alkermes plc has generated -8.8% fall in its revenue since last 3-months.

Net Profits:

Alkermes plc’s net profit fell -53.52% since last year same period to $-52.88Mn in the Q3 2019. On a quarterly growth basis, Alkermes plc has generated -25.93% fall in its net profits since last 3-months.

Net Profit Margins:

Alkermes plc’s net profit margin fell -49.6% since last year same period to -20.72% in the Q3 2019. On a quarterly growth basis, Alkermes plc has generated -38.08% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Alkermes plc post its latest quarter earnings

EPS Estimate Current Quarter
-0.12
EPS Estimate Current Year
-0.12

Highlights

EPS Estimate Current Quarter:

Alkermes plc’s earning per share (EPS) estimates for the current quarter stand at -0.12 - a -518.18% fall from last quarter’s estimates.

EPS Estimate Current Year:

Alkermes plc’s earning per share (EPS) estimates for the current year stand at -0.12.

Key Ratios

Key ratios of the Alkermes plc post its Q1 2023 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

Alkermes plc’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2023. This indicates that the Alkermes plc has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2018-02-16
0.23
0.31
34.78%
2017-07-27
-0.01
0.01
200%
2017-04-27
-0.09
-0.18
-100%
2017-10-26
-0.01
0.03
400%

Company Information

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

Organisation
Alkermes plc
Headquarters
Connaught House, Dublin, Ireland, 4
Employees
2280
Industry
Health Technology
CEO
Richard F. Pops